2023
Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO)
Tuan J, Sharma M, Kayani J, Davis M, McManus D, Topal J, Ogbuagu O. Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO). BMC Infectious Diseases 2023, 23: 258. PMID: 37101135, PMCID: PMC10130811, DOI: 10.1186/s12879-023-08198-9.Peer-Reviewed Original ResearchConceptsCOVID-19 patientsPregnant womenClinical outcomesEmergency departmentPositive SARS-CoV-2 testAdverse feto-maternal outcomesIntensive care unit admissionMild-moderate COVID-19Pregnant COVID-19 patientsPrimary composite clinical outcomeSARS-CoV-2 testComplete primary vaccinationComposite clinical outcomeCare unit admissionFeto-maternal outcomeMedical record reviewSARS-CoV-2 treatmentBetter clinical outcomesBody mass indexSickle cell diseaseCOVID-19SARS-CoV-2Neonatal complicationsPrimary vaccinationUnit admission
2022
Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH)
Tuan JJ, Zapata H, Barakat L, Andrews L, Behnegar A, Kim YW, Kayani J, Mutic S, Ryall L, Turcotte B, Critch-Gilfillan T, Zhao M, Salahuddin S, Gupta S, Sutton R, Friedland G, Emu B, Ogbuagu O. Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH). BMC Infectious Diseases 2022, 22: 744. PMID: 36131232, PMCID: PMC9491266, DOI: 10.1186/s12879-022-07737-0.Peer-Reviewed Original ResearchConceptsT cell responsesAnti-spike IgGVisit 3SARS-CoV-2Older PWHVisit 2Immune responseSingle-center longitudinal observational studyVirus-specific T cell responsesVaccine-induced humoral immunityLong-term protective immunityT cell immune responsesOlder peopleMedian age 61RBD IgG levelsPrimary study outcomeCOVID-19 vaccinationImmune response evaluationLongitudinal observational studyCOVID-19 vaccineWilcoxon signed-rank testBNT162b2 boosterBNT162b2 vaccinationCD8 responsesDetectable CD4De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report
Gandhi S, Klein J, Robertson AJ, Peña-Hernández MA, Lin MJ, Roychoudhury P, Lu P, Fournier J, Ferguson D, Mohamed Bakhash SAK, Catherine Muenker M, Srivathsan A, Wunder EA, Kerantzas N, Wang W, Lindenbach B, Pyle A, Wilen CB, Ogbuagu O, Greninger AL, Iwasaki A, Schulz WL, Ko AI. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. Nature Communications 2022, 13: 1547. PMID: 35301314, PMCID: PMC8930970, DOI: 10.1038/s41467-022-29104-y.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionVirologic responsePersistent SARS-CoV-2 infectionResistance mutationsPre-treatment specimensB-cell deficiencyRemdesivir resistanceRemdesivir therapyViral sheddingCase reportAntiviral agentsPatientsCombinatorial therapyInfectionTherapyWhole-genome sequencingTreatmentImportance of monitoringDe novo emergenceFold increaseRNA-dependent RNA polymeraseNovo emergencePotential benefitsMutationsIndolentSafety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study
Sridhar S, Joaquin A, Bonaparte MI, Bueso A, Chabanon AL, Chen A, Chicz RM, Diemert D, Essink BJ, Fu B, Grunenberg NA, Janosczyk H, Keefer MC, Rivera M DM, Meng Y, Michael NL, Munsiff SS, Ogbuagu O, Raabe VN, Severance R, Rivas E, Romanyak N, Rouphael NG, Schuerman L, Sher LD, Walsh SR, White J, von Barbier D, de Bruyn G, Canter R, Grillet MH, Keshtkar-Jahromi M, Koutsoukos M, Lopez D, Masotti R, Mendoza S, Moreau C, Ceregido MA, Ramirez S, Said A, Tavares-Da-Silva F, Shi J, Tong T, Treanor J, Diazgranados CA, Savarino S. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study. The Lancet Infectious Diseases 2022, 22: 636-648. PMID: 35090638, PMCID: PMC8789245, DOI: 10.1016/s1473-3099(21)00764-7.Peer-Reviewed Original ResearchConceptsHigh-dose groupLow-dose groupMedium-dose groupGeometric mean titresAdverse eventsRecombinant protein vaccineCOVID-19 vaccineSecond vaccinationSARS-CoV-2Day 36Antigen doseAdverse reactionsProtein vaccineMedical conditionsVaccine-related serious adverse eventsHigh-risk medical conditionsInteractive response technology systemAntibody geometric mean titresPre-existing medical conditionsCandidate vaccine formulationsCoV2 preS dTMPrevious phase 1Primary immunogenicity objectivePseudovirus neutralization assayUnsolicited adverse events
2021
Facing COVID-19 in Liberia: Adaptations of the Resilient and Responsive Health Systems Initiative
Marsh RH, Plyler C, Miller M, Klar R, Adeiza M, Wachekwa I, Koomson F, Garlo JL, Kruah K, Lake SC, Matte R, Cook R, Maweu D, Kerr L, Ogbuagu O, Talbert-Slagle K, Dahn B. Facing COVID-19 in Liberia: Adaptations of the Resilient and Responsive Health Systems Initiative. Annals Of Global Health 2021, 87: 101. PMID: 34707981, PMCID: PMC8499715, DOI: 10.5334/aogh.3245.Commentaries, Editorials and LettersConceptsCommunity health worker involvementHealth system initiativesHealth worker involvementCOVID-19 pandemicHealth service impactsResponsive health systemHIV targetsHealth outcomesPatient volumeHealth workforceTelehealth servicesHealth systemOngoing educationService deliveryCOVID-19Safety protocolsClinical didacticsPandemicDirect service deliveryWorkforce programsFourth yearTraining impactEducational programsDeliveryHIVRace and ethnicity do not impact eligibility for remdesivir: A single-center experience
Pischel L, Walelo M, Benson J, Osborn R, Schrier R, Tuan J, Barakat L, Ogbuagu O. Race and ethnicity do not impact eligibility for remdesivir: A single-center experience. PLOS ONE 2021, 16: e0250735. PMID: 33956849, PMCID: PMC8101938, DOI: 10.1371/journal.pone.0250735.Peer-Reviewed Original ResearchConceptsClinical trialsExclusion criteriaSingle health care systemObservational cohort studySingle-center experienceClinical trial criteriaTime of presentationMedical record chartsNon-Hispanic whitesEthnic minority enrollmentSimilar ratesHealth care systemCohort studyTrial criteriaMultiple therapiesInclusion criteriaRecord chartsEthnic groupsRemdesivirCare systemTrialsSelf-identified WhiteEligibilityWhite participantsMultiple potential barriersA new positive SARS-CoV-2 test months after severe COVID-19 illness: reinfection or intermittent viral shedding?
Tuan J, Spichler-Moffarah A, Ogbuagu O. A new positive SARS-CoV-2 test months after severe COVID-19 illness: reinfection or intermittent viral shedding? BMJ Case Reports 2021, 14: e240531. PMID: 33542020, PMCID: PMC8098910, DOI: 10.1136/bcr-2020-240531.Peer-Reviewed Case Reports and Technical NotesConceptsSARS-CoV-2 RNA testSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2SARS-CoV-2 reinfectionSevere COVID-19 illnessRespiratory syndrome coronavirus 2COVID-19 reinfectionLong asymptomatic periodCOVID-19 illnessSyndrome coronavirus 2Intermittent viral sheddingAsymptomatic periodViral sheddingRNA testCoronavirus 2Clinical managementPersistent infectionDisease 4Molecular testingReinfectionRNA PCRCurrent presentationPotential casesMonthsPatients
2020
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
Spinner CD, Gottlieb RL, Criner GJ, López J, Cattelan AM, Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, Chai LYA, Roestenberg M, Tsang OTY, Bernasconi E, Le Turnier P, Chang SC, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wang H, Gaggar A, Brainard DM, McPhail MJ, Bhagani S, Ahn MY, Sanyal AJ, Huhn G, Marty FM. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19. JAMA 2020, 324: 1048-1057. PMID: 32821939, PMCID: PMC7442954, DOI: 10.1001/jama.2020.16349.Peer-Reviewed Original ResearchMeSH KeywordsAdenosine MonophosphateAdministration, IntravenousAgedAlanineAntiviral AgentsBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentDrug Administration ScheduleFemaleHospitalizationHumansMaleMiddle AgedOdds RatioPandemicsPatient AcuityPneumonia, ViralSARS-CoV-2Treatment OutcomeConceptsStandard care groupRemdesivir groupStandard careModerate COVID-19Initiation of treatmentClinical statusCare groupDay 11Acute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionModerate COVID-19 pneumoniaSyndrome coronavirus 2 infectionSevere coronavirus disease 2019Effect of remdesivirRemdesivir-treated patientsCoronavirus 2 infectionOpen-label trialPlacebo-controlled trialPrimary end pointUncertain clinical importanceCOVID-19 pneumoniaCoronavirus disease 2019COVID-19Significant differencesStatus distributionTransmission risk of respiratory viruses in natural and mechanical ventilation environments: implications for SARS-CoV-2 transmission in Africa
Sopeyin A, Hornsey E, Okwor T, Alimi Y, Raji T, Mohammed A, Moges H, Onwuekwe EVC, Minja FJ, Gon G, Ogbuagu O, Ogunsola F, Paintsil E. Transmission risk of respiratory viruses in natural and mechanical ventilation environments: implications for SARS-CoV-2 transmission in Africa. BMJ Global Health 2020, 5: e003522. PMID: 32863269, PMCID: PMC7462043, DOI: 10.1136/bmjgh-2020-003522.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements